Are we measuring what matters most on uptake to medicines in England?

16 November 2021 - VPAS is a voluntary agreement between the UK government and the Association of the British Pharmaceutical ...

Read more →

Drug Utilisation Sub-Committee outcome statement

5 November 2021 - The Outcome Statement from the October 2021 Drug Utilisation SubCommittee meeting is now available. ...

Read more →

Patient and payer incentives to use patented brand name drugs vs authorised generic drugs in Medicare Part D

18 October 2021 - This cross-sectional study of Medicare formulary and pricing data for quarter 3 of 2020 found that most ...

Read more →

Real world use of and spending on new oral targeted cancer drugs in the US (2011-2018)

18 October 2021 - In this cross-sectional study among 37 348 patients who received 1 or more of 44 new oral targeted ...

Read more →

Sales of Biogen’s costly new Alzheimer’s drug fall far short of expectations

20 October 2021 - The drug maker Biogen reported on Wednesday that Aduhelm, its new Alzheimer’s drug, brought in $300,000 ...

Read more →

Docs ‘use rubber stamp for drugs’

9 October 2021 - Pharmacists have raised the alarm over the influence of a US pharmaceutical corporation on Australian doctors ...

Read more →

Barriers to US biosimilar market growth: lessons from biosimilar patent litigation

6 August 2021 - High biologic drug prices have placed substantial strain on the US health care system.  ...

Read more →

Competition from biosimilars drives price reductions for biologics in the French single payer health system

6 August 2021 - France has a single payer health insurance system that has the authority to impose pharmaceutical price reductions ...

Read more →

Full FDA approval is needed to overcome vaccine hesitancy

26 July 2021 - As the Delta variant spreads, what is the agency waiting for? ...

Read more →

Biogen sees heavy patient interest in new Alzheimer’s drug

22 July 2021 - Company pushed back against criticism of drug’s effectiveness and approval, saying trial data supported use. ...

Read more →

Biogen Alzheimer's drug slow to take off as U.S. Medicare wrestles with coverage

21 July 2021 - U.S. hospitals that were expected to be early adopters of Biogen’s Alzheimer’s drug have treated only a ...

Read more →

Drug Utilisation Subcommittee outcome statement

21 July 2021 - The outcome statement from the June 2021 Drug Utilisation Subcommittee meeting is now available. ...

Read more →

DUSC utilisation analysis public release documents

13 July 2021 - The utilisation analysis public release documents from the February 2021 DUSC meeting are now available. ...

Read more →

Factors associated with generic drug uptake in the United States, 2012 to 2017

19 June 2021 - In the United States, brand-name prescription drugs remain expensive until market exclusivity ends and lower cost generics ...

Read more →

Uptake of medicines for type 2 diabetes mellitus

15 June 2021 - Empagliflozin (with and without metformin hydrochloride) has been funded since 1 February 2021. It is funded for ...

Read more →